Andreas Wallnöfer is a senior executive leader with more than 25 years experience in the pharmaceutical industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Leadership Team and Portfolio Committee. At Roche, he served 2007-2009 as Global Head of Clinical Research & Exploratory Development and Senior Vice President. After Roche’s acquisition of Genentech he was appointed in 2010 Head of Roche pRED Development and later took on the role of Head of Cardiovascular & Metabolism Disease (CVM). After the company decided, – for strategic reasons -, to exit CVM, he left Roche in 2015 and founded a Life Sciences Consulting company. In 2016, Dr. Wallnöfer joined BioMedPartners, a leading Swiss Venture Capital company and became partner in the BioMedInvest III fund, From summer 2016 to April 2017, he acted as interim Head of Development at Polyphor. During this time, he revised the clinical development plans and led, with a core team, the company’s most advanced project, murepavadin, successfully through End of Phase 2 meetings with FDA.